Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study Meeting Abstract


Authors: Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; McMillan, A. K.; Kim, T. M.; Kim, W. S.; Hertzberg, M.; Ozcan, M.; Penuel, E.; Cheng, J.; Hirata, J. M.; Ku, G.; Flowers, C.
Abstract Title: Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419700021
PROVIDER: wos
Notes: Meeting Abstract: 2821 -- Source: Wos